Vitiligo Update

Seminars in Cutaneous Medicine and Surgery

Volumn 28, Issue 2, 2009, Pages 86-92

  Halder, Rebat M ^a   Chappell, Johnathan L ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CATALASE; CLOBETASOL; CORTICOSTEROID; COSMETIC; DEXAMETHASONE; EFALIZUMAB; METHOXSALEN; MONOBENZONE; PIMECROLIMUS; PSEUDOCATALASE; STEROID; SUNSCREEN; TACROLIMUS; UNCLASSIFIED DRUG;

ACNE; ANTIOXIDANT ACTIVITY; BURN; CLINICAL ASSESSMENT; DEPIGMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; EPSTEIN BARR VIRUS; EXCIMER LASER; GROUP THERAPY; HEPATITIS C VIRUS; HEREDITY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERPIGMENTATION; HYPERTRICHOSIS; IMMUNE SYSTEM; LABORATORY TEST; LIGHT DAMAGE; MENSTRUAL IRREGULARITY; OXIDATIVE STRESS; PATHOGENESIS; PATIENT ASSESSMENT; PATIENT COUNSELING; PHOTOTOXICITY; PSORIASIS; PSYCHOTHERAPY; PUVA; REVIEW; SIDE EFFECT; SKIN PRURITUS; SKIN SURGERY; SUNBURN; ULTRAVIOLET B RADIATION; VITILIGO; WEIGHT GAIN;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; VITILIGO;

EID: 67650073260     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2009.04.008     Document Type: Review

References (34)

1. Halder R., and Taliaferro S. Vitiligo. In: Wolff K., Goldsmith L., Katz S., Gilchrest B., Paller A., and Lefell D. (Eds). Fitzpatrick's Dermatology in General Medicine, Vol 1. ed 7 (2008), McGraw-Hill, New York Vol 1
2. Halder R., Nandedkar M., and Neal K. Pigmentary disorders in pigmented skins. In: Halder R. (Ed). Dermatology and Dermatological Therapy of Pigmented Skin. ed 1 (2005), Informa Healthcare, New York, NY vol 5
3. Gavalas N.G., Akhtar S., Gawkrodger D.J., et al. Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. Biochem Biophys Res Commun 345 (2006) 1586-1591
4. Casp C.B., She J.X., and McCormack W.T. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res 15 (2002) 62-66
5. Bystryn J.C. Immune mechanisms in vitiligo. Clin Dermatol 15 (1997) 853-861
6. Palermo B., Campanelli R., Garbelli S., et al. Specific cytotoxic T lymphocyte responses against Melan A/Mart1, tyrosinase and gp100 in vitiligo by the use of major histocompatability complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117 (2001) 326-332
7. Ongenae K., Van Geel N., and Naeyaert J. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16 (2003) 90-100
8. Onay H., Pehlivan M., Alper S., et al. Might there be a link between mannose binding lectin and vitiligo?. Eur J Dermatol 17 (2007) 146-148
9. Hazneci E., Karabulut A.B., Oztürk C., et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 44 (2005) 636-640
10. Tu C., Zhao D., and Lin X. Levels of neuropeptide Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 27 (2001) 178-182
11. Grimes P.E., Sevall J.S., and Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 35 (1996) 21-26
12. Akbayir N., Gukdemir G., Mansur T., et al. Is there any relationship between hep C virus and vitiligo?. J Clin Gastroenterol 38 (2004) 815-817
13. Niamba P., Traore A., and Taieb A. Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy. Ann Dermatolo Venereol 134 (2007) 272-273
14. Gawkrodger D.J., Ormerod A.D., Shaw L., et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 159 (2008) 1051-1076
15. Sharquie K.E., Mehenna S.H., Naji A.A., et al. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol 26 (2004) 108-112
16. Papadopoulos L., Bor R., and Legg C. Coping with the disfiguring effects of vitiligo: A preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 72 (1999) 385-396
17. Cockayne S., Messenger A.G., and Gawkrodger D. Vitiligo treated with topical corticosteroids: Children with head and neck involvement respond well. J Am Acad Dermatol 46 (2002) 964-965
18. Kandil E. Treatment of vitiligo with 0.1 percent betamethasone 17-valerate in isopropyl alcohol-a double-blind trial. Br J Dermatol 91 (1974) 457-460
19. Clayton R. A double-blind trial of 0.05% clobetasol propionate in the treatment of vitiligo. Br J Dermatol 96 (1977) 71-73
20. Ostovari N., Passeron T., Lacour J.P., et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 142 (2006) 252
21. Passeron T., Ostovari N., Zakaria W., et al. Topical tacrolimus and the 308-nm excimer laser: A synergistic combination for the treatment of vitiligo. Arch Dermatol 140 (2004) 1065
22. Coskun B., Saral Y., and Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 15 (2005) 88-91
23. Chiaverini C., Passeron T., and Ortonne J.P. Treatment of vitiligo by topical calcipotriol. J Eur Academy Dermatol Vereol 16 (2002) 137-138
24. Schallreuter K. State of the art on the treatment of vitiligo with pseudocatalase. J Eur Acad Dematol Venereol 17 suppl (2003) 30
25. Schallreuter K., Moore J., Behrens-Williams S., et al. Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase. Int J Dermatol 41 (2002) 482
26. Schallreuter K., Moore J., Wood J.M., et al. In vivo and in vitro evidence for hydrogen peroxide accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol 4 (1999) 91
27. Radakovic F.S., Furnsinn-Friedl A.M., Honigsmann H., et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 44 (2001) 814-817
28. Wakkee M., Assen Y.J., Thio H.B., et al. Repigmentation of vitiligo during efalizumab. J Am Acad Dermatol 59 (2008) S57-S58
29. Roelandts R. Photo(chemo) therapy for vitiligo. Photodermatology Phoimmunol Photomed 19 (2003) 1-4
30. Parsad D., Kanwar A.J., and Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 20 (2006) 175-177
31. Westerhof W., and Nieuweber-Krobotova L. Treatment of vitiligo with UVB radiation vs. topical psoralen plus UVA. Arch Dermatol 133 (1997) 1525-1528
32. Esposito M., Soda R., Costanzo A., et al. Treatment of vitiligo with the 308 nm excimer laser. Clin Exp Dermatol 29 (2004) 133-137
33. Halder R., and Nordlund J.J. Topical treatment of pigmentary disorders. In: Nordlund J.J., et al. (Ed). The Pigmentary System: Physiology and Pathophysiology (1998), Oxford University Press, New York, NY 972
34. Kim H.Y., and Kang K.Y. Epidermal grafts for the treatment of stable and progressive vitiligo. J Am Acad Dermatol 40 (1999) 412-417